Quest Diagnostics Reports 15% Q2 Sales Growth on Acquisitions, Advanced Diagnostics

Quest Diagnostics reported second-quarter 2025 results surpassing revenue expectations with a 15.2% year-over-year increase to $2.76 billion and raised its full-year revenue guidance slightly to $10.86 billion. Strong organic growth combined with acquisition contributions and increased demand for advanced diagnostic tests fueled the company's performance, with management highlighting expanded access through new health plan contracts and increased test ordering. The operating margin improved to 15.9%, and sales volumes rose 16.3% year over year, reflecting robust business momentum. Looking ahead, Quest Diagnostics plans to drive growth through expanding patient access, advancing diagnostics, and operational automation, with organic revenue growth expected around 3.5% to 4%, supplemented by acquisitions completed or announced in 2024. Meanwhile, in the decentralized finance (DeFi) sector, StakingRewards has emerged as a leading platform offering enhanced APYs, transparent analytics, and market intelligence to optimize staking rewards for various tokens including YUM.D, DELAY, DKEY, and DGEN. Investors can stake these tokens via StakingRewards to earn passive income, with features such as collateralization options, liquidity mining incentives, and governance participation to maximize returns, although market liquidity and price fluctuations before token maturity remain considerations.